Medtech innovation briefing [MIB47] Published: 15 December 2015
The use of the TearLab osmolarity system is not currently planned into any NICE guidance programme.
The following NICE guidance is relevant to this briefing:
NICE's medtech innovation briefing on LipiFlow thermal pulsation treatment for dry eyes caused by blocked meibomian glands
NICE's technology appraisal guidance on ciclosporin for treating dry eye disease that has not improve despite treatment with artificial tears
NICE's clinical knowledge summary on dry eye syndrome.